GeneDx Holdings Corp. Class A (WGS)
NASDAQ: WGSHealth CareMedical/Nursing ServicesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 68.53 0.00%
WGS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.04B
- Forward P/E
- 57.18
- EPS (TTM)
- -$3.63
- Dividend yield
- None
- 52-week range
- 32.21 – 170.87
- Day range
- 68.39 – 71.43
- Volume / Avg
- 659.22K / 726.80K
- Beta
- —
- Shares outstanding
- 29.82M
- Next earnings
- Oct 27, 2026
52-week range
WGS stock today
GeneDx (WGS) closed at $68.53 on Oct 7, down 4.18% (-$2.99), versus the S&P 500's 0.22% decline. Shares are 59.9% below their 52-week high of $170.87, set on Dec 2, 2025 and 112.8% above the 52-week low of $32.21, in the middle of the past year's range. WGS is down 47.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 43.3%.
GeneDx has posted a net loss over the last twelve months (EPS of -$3.63), so its P/E ratio is not meaningful. The company is scheduled to report Sep/2026 results on Oct 27; analysts expect EPS of $0.07.
Summary generated from market data by MetaCap's automated system. Methodology
About GeneDx
Company profileGeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing.
- Sector
- Health Care
- Industry
- Medical/Nursing Services
- CEO
- Ms. Katherine A. Stueland
- Headquarters
- Stamford, CT
- Employees
- 1,300
- IPO year
- 2020
- Website
- genedx.com
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$93.50+36.44%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $0.07
GeneDx peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ADUSAddus HomeCare Corporation | 113.27 | +0.10% | $2.12B | vs WGS |
| PRVAPrivia Health Group Inc. | 20.30 | +0.10% | $2.59B | vs WGS |
| AVAHAveanna Healthcare Holdings Inc. | 12.31 | +0.74% | $2.69B | vs WGS |
| PNTGThe Pennant Group Inc. | 39.62 | -0.84% | $1.38B | vs WGS |
| OMDAOmada Health Inc. | 20.89 | +0.77% | $1.28B | vs WGS |
| INNVInnovAge Holding Corp. | 9.13 | +1.44% | $1.25B | vs WGS |
| USPHU.S. Physical Therapy Inc. | 82.96 | -0.80% | $1.24B | vs WGS |
| PIIIP3 Health Partners Inc. Class A | 5.63 | +5.62% | $1.15B | vs WGS |
Indexes, lists and sector
GeneDx stock FAQ
What is GeneDx's stock price today?
WGS last traded at $68.53 as of Oct 7, 4:00 PM EDT, down 4.18% on the day. Prices are delayed at least 15 minutes.
Does GeneDx pay a dividend?
No. GeneDx does not currently pay a regular cash dividend.
When is GeneDx's next earnings date?
GeneDx is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $0.07.
Who is GeneDx's CEO?
Ms. Katherine A. Stueland is the chief executive officer of GeneDx Holdings Corp. Class A, which has about 1,300 employees.
Has WGS ever split its stock?
Yes. The most recent WGS stock split was a 1-for-33 split on May 4, 2023.
What is the WGS 52-week high?
The 52-week high for WGS is $170.87 and the 52-week low is $32.21. The stock is currently 59.9% below its high.